About
Partial fatty acid oxidation (pFOX) inhibitor
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
979
By Phase
PHASE2: 5
By Status
COMPLETED: 3RECRUITING: 1SUSPENDED: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT07023614Lead Sponsor
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
PHASE2Recruiting
165 participants
Started: Oct 31, 2025 · Completed: Dec 31, 2026
NCT04306237Lead Sponsor
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
PHASE2Suspended
640 participants
Started: Nov 30, 2023 · Completed: Apr 30, 2025
NCT04826185Lead Sponsor
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
PHASE2Completed
67 participants
Started: Jun 14, 2021 · Completed: Sep 18, 2023
NCT04826172Lead Sponsor
Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)
PHASE2Completed
58 participants
Started: Apr 23, 2021 · Completed: Sep 21, 2023
NCT04826159Lead Sponsor
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
PHASE2Completed
49 participants
Started: Apr 21, 2021 · Completed: Aug 6, 2024
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...